A New England Journal of Medicine study published yesterday found success in administering dostarlimab, an immunotherapy drug, to a group of 103 cancer patients instead of traditional methods such as chemotherapy, radiation or surgery. All 49 patients of the first cohort, who had rectal cancer, had their cancer disappear and continued treatment with nonoperative management. The second cohort of patients had other cancers, and 35 of 54 in that group had their cancer eradicated. Thirty-three continued with nonoperative treatment. 

Related News Articles

Headline
A JAMA study released Jan. 22 found that colorectal cancer is the leading cause of cancer deaths in people under age 50. The study examined cancer mortality in…
Headline
The five-year survival rate for all cancers in the U.S. has reached 70% for the first time, according to a report published Jan. 13 by the American Cancer…
Headline
A study released Jan. 12 by the Journal of the American College of Cardiology analyzed the current state of heart health in the U.S., highlighting the…
Headline
The Health Resources and Services Administration yesterday announced updated cervical cancer screening guidelines, including optional self-collection of…
Headline
The Centers for Medicare & Medicaid Services Dec. 11 announced the launch of the Make America Healthy Again: Enhancing Lifestyle and Evaluating Value-based…
Headline
A study published Dec. 3 by the New England Journal of Medicine found that one dose of the HPV vaccine could be as effective as two in preventing cervical…